Children with severe, therapy-resistant asthma more likely to have poorer lung function: SARP

Discussed in Pediatric Allergy, Immunology, and Pulmonology journal

A subset of children with asthma suffers from severe, treatment-resistant disease associated with more illness and greater allergic hypersensitivity, according to the results of the National Heart, Blood, and Lung Institute's Severe Asthma Research Program (SARP), presented in a recently published article in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article is available free online at www.liebertpub.com/pai

Asthma is the most common chronic lung disease of children, with more than 6.6 million affected in the U.S. Although relatively few children have severe asthma, they account for almost half of asthma related expenditures.

SARP compared severe, therapy-resistant asthma in children and adults and identified age-specific characteristics of the disease. The results suggest that there are distinguishable clinical features of severe asthma that can be identified early in life. Authors Anne Fitzpatrick, PhD from Emory University (Atlanta, GA) and William Gerald Teague, MD from the University of Virginia (Charlottesville) review the highlights of the SARP findings in an article entitled "Severe Asthma in Children: Insights from the National Heart, Lung, and Blood Institute's Severe Asthma Research Program". They conclude that children with severe, therapy-resistant asthma are more likely to have poorer lung function and higher levels of allergic sensitization and to be of African American or mixed ancestry. Their findings suggest that children as young as 6 years with severe asthma may already have structural airway changes.

"Identifying the features associated with severe, treatment-resistant asthma in children will allow us to better understand this illness and develop better treatments for these children who spend so much time struggling to breathe," says Harold Farber, MD, MSPH, Editor of Pediatric Allergy, Immunology, and Pulmonology, and Associate Professor of Pediatrics, Section of Pulmonology, Baylor College of Medicine, Houston, TX.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options